Based on 1 publication(s) in Google Scholar
IWP-2 (GMP) is >IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 686770-61-6
- Formel: C22H18N4O2S3
- Molecular Weight:466.60
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) IWP-2 (GMP)
More
Biologische Aktivität
IC50: 27 nM (Wnt)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CAPAN-1 | EC50 |
2.05 μM
Compound: IWP-2
|
Antiproliferative activity against human Capan1 cells after 48 hrs by MTT assay
Antiproliferative activity against human Capan1 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
| HEK293 | EC50 |
2.76 μM
Compound: IWP-2
|
Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
| HT-29 | EC50 |
4.67 μM
Compound: IWP-2
|
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
| MIA PaCa-2 | EC50 |
1.9 μM
Compound: IWP-2
|
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
| PANC-1 | EC50 |
2.33 μM
Compound: IWP-2
|
Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay
Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
| SW-620 | EC50 |
1.9 μM
Compound: IWP-2
|
Antiproliferative activity against human SW620 cells after 48 hrs by MTT assay
Antiproliferative activity against human SW620 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
IWP-2 (GMP) (2?μM, in the first 4?days of Stage IV induction medium) reprograms human somatic cells to pluripotent stem cells[1].
IWP-2 (GMP) (5?μM, day 3 to 5) induces cardiac differentiation of hiPSCs[2].
IWP-2 (GMP) (5 μM, day 1 to 3) increasing the expression of cardiac progenitors and cardiac genes (MYL2, TNNI3, and TNNT2) in hiPSCs[3].
IWP-2 (GMP) (5 μM, day 5-7) together with PIP-S2 induces cardiac mesoderm differentiates into functional cardiomyocytes[4].
IWP-2 (GMP) (5 μM, treated at day 3) induces cardiomyocyte differentiation when applied following a pretreatment with Laduviglusib (GMP) (HY-10182G)[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:hiPSCs
-
Concentration:5 μM
-
Incubation Time:day 1 to 3
-
Result:Reduced the expression of anti-cardiac mesoderm genes, and increased the expression of cardiac progenitors and cardiac genes (MYL2, TNNI3, and TNNT2).
Chemical Information
-
CAS. Nr. 686770-61-6
-
Appearance Solid
-
Molecular Weight 466.60
-
Formel C22H18N4O2S3
-
Color White to off-white
-
SMILES
O=C(NC1=NC2=CC=C(C)C=C2S1)CSC3=NC(CCS4)=C4C(N3C5=CC=CC=C5)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Protoc
Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks. [Abstract]2024 Jul;19(7):1911-1939. PMID: 38548938
Lösungsmittel & Löslichkeit
DMSO : 2 mg/mL (4.29 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Guan J et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022;605(7909):325-331. [Content Brief]
[2]. Hamad S, et al. Generation of human induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer and scalable 3D suspension bioreactor cultures with reduced batch-to-batch variations. Theranostics. 2019 Sep 25;9(24):7222-7238. [Content Brief]
[3]. Le MNT, et al. Auto/paracrine factors and early Wnt inhibition promote cardiomyocyte differentiation from human induced pluripotent stem cells at initial low cell density. Sci Rep. 2021 Nov 2;11(1):21426. [Content Brief]
[4]. Taniguchi J, et al. A synthetic DNA-binding inhibitor of SOX2 guides human induced pluripotent stem cells to differentiate into mesoderm. Nucleic Acids Res. 2017 Sep 19;45(16):9219-9228. [Content Brief]
[5]. Lian X, Zhang J, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc. 2013 Jan;8(1):162-75. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1432 mL | 10.7158 mL | 21.4316 mL | 53.5791 mL |